Baked goods

ABSTRACT

Compositions and method comprising lactic acid-producing bacteria in baked goods.

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a Rule 53(b) Continuation of U.S. application Ser.No. 16/543,491, filed Aug. 16, 2019, which is a Rule 53(b) Continuationof U.S. application Ser. No. 12/229,862, filed Aug. 27, 2008, now U.S.Pat. No. 10,383,342, which claims the benefit of U.S. ProvisionalApplication No. 60/966,897, filed Aug. 29, 2007, the contents of allwhich are hereby incorporated by reference in their respectiveentireties.

FIELD OF THE INVENTION

The present invention relates to the use of lactic acid-producingbacteria in baked goods.

BACKGROUND OF THE INVENTION

The gastrointestinal microflora plays a number of vital roles inmaintaining gastrointestinal tract function and overall physiologicalhealth. The growth and metabolism of the many individual bacterialspecies inhabiting the gastrointestinal tract depend primarily upon thesubstrates available to them, most of which are derived from the diet.(See e.g., Gibson G. R. et al., 1995. Gastroenterology 106: 975-982;Christl, S. U. et al., 1992. Gut 33: 1234-1238). These findings have ledto attempts to modify the composition and metabolic activities of thebacterial community through diet, primarily with probiotics, which arelive microbial food supplements.

Probiotic organisms arc non-pathogenic, non-toxigenic, retain viabilityduring storage, and survive passage through the stomach and smallintestine. Since probiotics do not generally permanently colonize thehost, they need to be ingested regularly for any health promotingproperties to persist.

SUMMARY OF THE INVENTION

The invention describes the use of acid-producing bacteria in bakedgoods for human or animal consumption. Specifically, the inventionprovides compositions comprising a baked composition of an edible starchand an isolated Bacillus coagulans bacterium and methods ofadministering probiotic bacterial spores to a human or other animal byproviding a baked good containing the spores to the human or otheranimal whereby the human or animal ingests the baked good and the sporesgerminate in the gastrointestinal tract (stomach or small intestine).Germination of spores and/or colonization of gastrointestinal tissue bythe administered bacterial spores or cells is assessed by detecting theprobiotic microorganism in the stool of the individual.

An exemplary baked good includes a bread, a cake, a pie, a tart, apastry, a candy bar, an energy bar, a food bar, granola, a granola bar,a quiche, a cookie, cereal, a pizza, a corn chip, a tortilla chip, apotato chip, a baked cracker, a dehydrated vegetable, a dehydratedfruit, or a treat for companion animals. In another aspect, the bakedgood includes any good comprising flour. In yet another aspect, thebaked good of the invention includes any good that is heated, e.g.,baked (exposure of dry heat). Preferably, the baked good is a muffin. Inone aspect, the baked good is a blueberry bran muffin.

Optionally, the baked composition also includes a fat. Suitable fatsinclude oils, butters, shortenings, artificial lipids, synthetic fats,and a fat substitutes. In another aspect, the baked composition alsoincludes a sugar, sugar substitute, or artificial sweetener.

In one aspect, the isolated Bacillus coagulans comprise between about0.01% to about 50% by weight of the baked good. Optionally, the isolatedBacillus coagulans comprise between about 0.01% and about 10% by weightof the baked good. Preferably, the isolated Bacillus coagulans comprisebetween about 0.01% and about 0.1% by weight of the baked good.

The invention also provides bacterial species including Bacilluscoagulans, e.g., Bacillus coagulans Hammer, preferably Bacilluscoagulans Hammer strain Accession No. ATCC 31284, or one or more strainsderived from Bacillus coagulans Hammer strain Accession No. ATCC 31284(e.g., ATCC Numbers: GBI-20, ATCC Designation Number PTA-6085; GBI-30,ATCC Designation Number PTA-6086; and GBI-40, ATCC Designation NumberPTA-6087; see U.S. Pat. No. 6,849,256 to Parmer).

Optionally, the isolated Bacillus coagulans is in the form of a spore.Alternatively, the isolated Bacillus coagulans is in the form of avegetative cell. In another aspect, the isolated Bacillus coagulans isin the form of a mixture of vegetative cells and spores.

The invention also provides for methods of making a baked good, whereinthe baked good comprises a flour containing base mix and a liquidportion of water. Optionally, the method includes providing a flourcontaining base mix and a liquid portion of water; mixing the flourcontaining base mix and water to form a batter or dough; applying anisolated Bacillus coagulans bacterium to the batter or dough, and heatprocessing the batter or dough to cook the baked good. Alternatively,the method includes providing a flour containing base mix and a liquidportion of water; mixing the flour containing base mix and water to forma batter or dough, combining an isolated Bacillus coagulans bacteriumwith the batter or dough, and heat processing the batter or dough tocook the baked good.

Optionally, the isolated Bacillus coagulans is Bacillus coagulans Hammerstrain Accession No. ATCC 31284. In an exemplary embodiment, theisolated Bacillus coagulans is GBI-30 strain (ATCC Designation NumberPTA-6086). In one aspect, the isolated Bacillus coagulans is in the formof a spore. Alternatively, the isolated Bacillus coagulans is in theform of a vegetative cell. In a preferred embodiment, the isolatedBacillus coagulans comprise between 1% and 10% by weight of the bakedgood.

The invention also provides compositions comprising a dry mix for bakedgoods including a flour and an isolated Bacillus coagulans bacterium.

The Bacillus coagulans Hammer strains of the invention arenon-pathogenic and generally regarded as safe for use in human nutrition(i.e., GRAS classification) by the U.S. Federal Drug Administration(FDA) and the U.S. Department of Agriculture (USDA), and by thoseskilled in the art. Furthermore, the Bacillus coagulans Hammer strainsof the invention germinate at or below human body temperature, renderingthem useful as probiotics. Many Bacillus coagulans strains outside theHammer group have mostly industrial applications, little or nonutritional benefit, and environmental contaminants that have not beenevaluated for safety. Moreover, many other non-Hammer strains ofBacillus coagulans grow optimally at temperatures that exceed human bodytemperature and, thus, do not germinate efficiently in the human body.Such strains are less or not suitable as probiotics for humanconsumption.

Cited publications are incorporated herein by reference. Both theforegoing general description and the following detailed description andexamples are exemplary and explanatory only and are not restrictive ofthe invention as claimed.

DETAILED DESCRIPTION OF THE INVENTION

The present invention is directed to the discovery that non-pathogeniclactic acid-producing bacteria (i.e., “lactic acid bacteria”), such asthe exemplary Bacillus coagulans, are useful in baked compositions as aprobiotic.

Probiotic Lactic Acid-Producing Bacteria

A probiotic lactic acid-producing bacteria suitable for use in themethods and compositions of the invention produces acid and isnon-pathogenic. There are many suitable bacteria identified as describedherein, although the invention is not limited to currently knownbacterial species insofar as the purposes and objectives of the bacteriais described. The property of acid production is important to theeffectiveness of the probiotic lactic acid-producing bacteria of thisinvention.

The invention provides using a lactic acid-producing bacteria, such as aspore-forming Bacillus species, such as B. coagulans. Preferably, thespore-forming Bacillus species of the invention is B. coagulans Hammer.

Exemplary methods and compositions are described herein using Bacilluscoagulans as a probiotic. Purified and/or isolated Bacillus coagulans isparticularly useful as a probiotic in baked edible food products.Probiotic B. coagulans is non-pathogenic and is generally regarded assafe (i.e., GRAS classification) by the U.S. Federal Drug Administration(FDA) and the U.S. Department of Agriculture (USDA), and by thoseskilled in the art.

Bacillus coagulans is a non-pathogenic gram positive spore-formingbacteria that produces L(+) lactic acid (dextrorotatory) in fermentationconditions. It has been isolated from natural sources, such asheat-treated soil samples inoculated into nutrient medium (Bergey'sManual off Systemic Bacteriology, Vol. 2, Sneath, P. H. A., et al.,cds., Williams & Wilkins, Baltimore, Md., 1986). Purified B. coagulansstrains have served as a source of enzymes including endonucleases(e.g., U.S. Pat. No. 5,200,336); amylase (U.S. Pat. No. 4,980,180);lactase (U.S. Pat. No. 4,323,651); and cyclo-malto-dcxtringlucano-transferase (U.S. Pat. No. 5,102,800). B. coagulans has beenused to produce lactic acid (U.S. Pat. No. 5,079,164). A strain of Bcoagulans (referred to as L. sporogenes; Sakaguti & Nakayama (ATCC31284)) has been combined with other lactic acid producing bacteria andB. natto to produce a fermented food product from steamed soybeans (U.S.Pat. No. 4,110,477).

Bacterial species include Bacillus coagulans, e.g., Bacillus coagulansHammer, preferably Bacillus coagulans Hammer strain Accession No. ATCC31284, or one or more strains derived from Bacillus coagulans Hammerstrain Accession No. ATCC 31284 (e g., ATCC Numbers: GBI-20, ATCCDesignation Number PTA-6085; GBI-30, ATCC Designation Number PTA-6086;and GBI-40, ATCC Designation Number PTA-6087; see U.S. Pat. No.6,849,256 to Farmer).

Bacillus coagulans was previously mis-characterized as a Lactobacillusand labeled as Lactobacillus sporogenes (See Nakamura et al. 1988. Int.J. Syst. Bacteriol. 38: 63-73). However, initial classification wasincorrect because Bacillus coagulans produces spores and excretesL(+)-lactic acid through metabolism. Both of these characteristicsprovide key features to the utility of Bacillus coagulans. Thesedevelopmental and metabolic aspects required that the bacterium beclassified as a lactic acid Bacillus. In addition, it is not generallyappreciated that classic Lactobacillus species are unsuitable forcolonization of the gut due to their instability in the harsh (i.e.,acidic) pH environment of the bile, particularly human bile. Bycontrast, Bacillus coagulans is able to survive and colonize thegastrointestinal tract in the bile environment and even grown in thislow pH range.

Probiotic Activity of Bacillus coagulans

It is well-documented clinically that many species of bacterial, mycoticand yeast pathogens possess the ability to cause a variety ofgastrointestinal disorders including, but not limited to: disruption ofnormal gastrointestinal biochemical function, necrosis ofgastrointestinal tissues, and disruption of the bioabsorption ofnutrients, and like conditions. The probiotic microorganism-containingcompositions of the present invention inhibit these pathogens. Thus, thecompositions of the invention are useful in the prophylactic ortherapeutic treatment of conditions associated with infection by theseaforementioned pathogens.

In one aspect, a Bacillus coagulans strain is included in thecomposition in the form of vegetative cells. Alternatively, the Bacilluscoagulans strain is included in the composition in the form of spores.The invention also provides for including the Bacillus coagulans strainin the composition in the form of a dried cell mass, a stabilized paste,or a stabilized gel.

Because Bacillus spores are heat and pressure-resistant and can bestored as a dry power, they are particularly useful for formulation intoand manufacture of products such as the various baked products andcompositions described herein. A Bacillus species is well suited for thepresent invention, particularly species having the ability to formspores which arc relatively resistant to heat and other conditions,making them ideal for storage (shelf-life) in product formulations.

The Bacillus coagulans of the invention survives storage (shelf-life)from about 12 days to about 2 years; from about 1 month to about 18months; from about 3 months to about 1 year; or from about 6 months toabout 9 months. For example, spores baked into a muffin remain viableand germination-competent for the self-life of the muffin (e.g., 6-12days).

Micro-Encapsulation

In one aspect, the lactic-acid producing bacteria are incorporated intoa microcapsule coating prior to addition to the baked good, using anymicro-encapsulation process well-known in the art. The isolated Bacilluscoagulans are packaged, or encapsulated, within another material inorder to protect the bacteria from the surrounding environment. Thecapsules of the invention range in size from one-thousandth of amillimeter to seven millimeters. The internal ingredients of themicrocapsule are released from their shells in various ways, includingmechanical rupture of the capsule wall, dissolution of the wall, meltingof the wall and diffusion through the wall. Thus, micro-encapsulationprovides additional protection to the isolated Bacillus bacterium duringheat processing (baking) of the baked goods of the invention. Physicalmethods of micro-encapsulation include pan coating, air-suspensioncoating, centrifugal extrusion, vibrational nozzle, and spray-drying.Chemical methods of micro-encapsulation include interfacialpolymerization, in-situ polymerization, and matrix polymerization.

Alternatively, the lactic-acid producing bacteria is added to the bakedgood without micro-encapsulation.

Baked Goods

The invention is directed to the surprising discovery that lacticacid-producing bacteria, particularly Bacillus species, remain viableand retain their beneficial probiotic properties in heated/cooked bakedgoods, as the baked goods of the invention are heated to between about300° F. to about 475° F. for about 5 minutes; about 10 minutes; about 30minutes; or about 1 hour. In one aspect, the baked goods of theinvention are heated up to about 350° F. for about 14 minutes: about450° F. for about 17 minutes; or about 475° F. for about 6 minutes. Thepreferred heat and duration will vary depending upon the particularbaked good. In one aspect, muffins are heated up to about 350° F. toabout 375° F. for about 14 to about 20 minutes. In another aspect,cereal is heated up to about 475° F. for about 6 minutes.

As discussed further, the compositions are formulated in manyconfigurations because the bacterium is present as a vegetative cell oras a spore, or both, depending on the species and form of the probioticorganism. The cells/spores are present in a variety of compositionssuited for use in a baked good. In one aspect, the bacterium is presentas a mixture of spores and vegetative cells. Preferably, the bacteriumis present as at least 90% spores, e.g., 95%, 98%, or 99% spores.

An exemplary baked good includes a bread, a cake, a pie, a tart, apastry, a candy bar, an energy bar, granola, a granola bar, a quiche, acookie, cereal, a food bar, a pizza, a corn chip, a tortilla chip, apotato chip, a baked cracker, a dehydrated vegetable, or a treat forcompanion animals. In another aspect, the baked good includes any goodcomprising flour. In yet another aspect, the baked good of the inventionincludes any good that is heated. The invention provides for bakedcompositions baked/cooked in an oven. The compositions described hereinare baked, or dried by subjecting them to heat. Alternatively, the bakedcompositions are steam-heated using high heat and excessive moisture,e.g., from about 10% to about 50% w/w water/dough prior to baking.Preferably, the baked composition comprises about 30-50% w/wwater/dough; about 15-30% w/w water/dough; or about 5-15% w/wwater/dough prior to baking. The invention also provides forconfectionary compositions such as sweets, lollipops, candy bars,chocolate, and other sweet items of snack food.

Bread consists minimally of flour and water; salt is present in mostcases, and usually a leavening agent such as yeast is used; however, anywell-recognized method of making bread is used in the present invention.Optionally, the flour is wheat flour, rice flour, corn flour, rye flour,potato flour, millet flour, baking flour, graham flour or quinoa flour.In one aspect, the flour is self-rising or self-raising flour. In somecases, bread also contains some amounts of sugar, spices, fruit (such asraisins, pumpkins, bananas, strawberries, blueberries, and the like),vegetables (such as onion or zucchini, and the like), nuts, or seeds(such as caraway, sesame or poppy seeds). Optionally, a fat such as anoil (vegetable oil, corn oil, olive oil, grape seed oil, nut oil orfruit oil), butter, shortening, artificial lipid, synthetic fat, or afat substitute such as olestra is also present. In yet another aspect, asugar, sugar substitute, or artificial sweetener such as saccharin,sucralose or aspartame is present. Suitable baked goods include, but arenot limited to, buns, rolls, bagels, cookies, and pastries. Preferably,the baked good is a blueberry bran muffin.

The Bacillus bacterium is impregnated into the baked good during themanufacturing process of the baked good (e.g., added to the batter ordough mix). The pressure and heat resistance of Bacillus spores makesthem particularly suitable for incorporation into the baked good priorto heat processing (baking) to cook the baked good.

In one aspect, the probiotic lactic acid-producing bacteria isintroduced into or onto portions of the baked good by applying acomposition containing viable bacteria to the baked good during a stageof the manufacture of the baked good. Preferably, the spores and/orvegetative cells of the probiotic acid-producing bacteria are introducedinto batter or dough prior to baking the baked good. Alternatively, thebacteria is added during the baking process or after the baking processhas concluded.

Preferably, the Bacillus bacterium is introduced into the batter priorto cooking the baked good. The invention provides a batter comprising aliquid mixture, usually based on one or more flours combined withliquids, such as water, milk or beer. In one aspect, egg is included inthe batter. Optionally, a leavening agent is included in the mixture toaerate and fluff-up the batter as it cooks. In one embodiment, theviscosity of batter is very “still” (adhering to an upturned spoon).Alternatively, the viscosity of the batter is very “thin” (similar tosingle cream). Preferably, heat is applied to the batter by baking, inorder to cook the ingredients (thus rendering them palatable) and to“set” the batter into a solid form. Following the baking process, thebaked product is suitable for immediate human or animal consumption orfor freezing, i.e., to store the product for future consumption.

The invention also provides for applying the Bacillus bacterium to abaked good using any of a variety of known methods including, forexample, applying a powder, spray-drying the probiotic onto the bakedgood or soaking the baked good in a solution containing the probiotic.Optionally, the Bacillus bacterium is applied prior to cooking the bakedgood. Alternatively, the Bacillus bacterium is applied during or afterthe baking process has been completed.

The invention provides for a variety of methods for placing thebacterial composition onto a baked good. However, preferred methodsinclude a “spray-dry” method in which the baked good is exposed in a lowhumidity chamber to an atomized mix containing a liquid composition,where the chamber is subsequently exposed to approximately 80-110° F. todry the liquid, thereby impregnating the material of the baked good withthe components of the composition.

Atypical concentration is from approximately 1×10⁷ to 1×10¹² CFU, 1×10⁸to 1×10¹¹ CFU; or 1×10⁹ to 1×10¹⁰ CFU of viable bacterium or spores/intof external surface of baked good. Following drying, the baked good isready for immediate use, storage in a sterile package, or for freezing.

The active ingredients (i.e., live bacteria or extracellularcomponents), comprise about 0.01% to about 50% by weight of the finalcomposition, preferably 0.01% to 10% by weight of the final baked good.Preferably, the isolated Bacillus coagulans comprise between about 0.01%and about 0.1% by weight of the baked good.

In one aspect, the amount of bacteria is about 10⁴ to 10¹⁴ colonyforming units (CFU) of bacteria per gram of baked good (i.e., vegetativecells and/or bacterial spores), preferably 10⁵ to 10¹³ CFU/g. Morepreferably, the concentrations are 10⁸ to 10¹³ CFU/g; 10⁹ to 10¹² CFU/g;or 10¹⁰ to 10¹¹ CFU/g. In one aspect, the amount of bacteria is about1×10⁶ CFU per baked good. Alternatively, the amount of bacteria is about2×10¹⁰ CFU/5 lbs of batter. The actual amount in a composition will varydepending upon the amounts of composition to be dispersed into the bakedgood and upon routes of dispersal.

In one aspect, the isolated Bacillus coagulans comprise between about0.01% to about 10%; 0.01% to about 1%; or about 0.05% to about 0.1% byweight of the baked good. Optionally, the isolated Bacillus coagulanscomprise about 1 mg to about 10 g; about 10 mg to about 1 g; or about 25mg to about 75 mg by weight of the baked good.

In one aspect, the finished baked good is frozen and stored in a sterilepackage prior to consumption. The invention also provides for storingthe baked good in a sterile package at room temperature prior toconsumption. Alternatively, the baked goods are consumed immediately. Inone aspect, the Bacillus coagulans spores survive storage (shelf-life),i.e. retain viability or the ability to germinate at physiologicalconditions (e.g., ingestion), from about 12 days to about 2 years: fromabout 1 month to about 18 months; from about 3 months to about 1 year;or from about 6 months to about 9 months. In one aspect, the Bacilluscoagulans of the invention survives storage (shelf-life) in muffins forat least about 12 days. In another aspect, the Bacillus coagulans of theinvention survives storage (shelf-life) in frozen pizza for at leastabout 2 years. In yet another aspect, the Bacillus coagulans of theinvention survives storage (shelf-life) in food bars for at least about6 to at least about 18 months.

Example 1: Preparation of Bacillus coagulans Cultures

Bacillus coagulans Hammer bacteria (ATCC Accession No. 31284) wasinoculated and grown to a cell density of about 10⁸ to 10⁹ cells/ml innutrient broth containing 5 g Peptone, 3 g Meat extract, 10-30 mg MnSO₄,and 1,000 ml distilled water, adjusted to pH 7.0, using a standardairlift fermentation vessel at 30° C. The range of MnSO₄ acceptable forsporulation is 1 mg/l to 1 g/l. The vegetative cells can activelyreproduce up to 45° C., and the spores are stable up to 90° C. Afterfermentation, the B. coagulans bacterial cells or spores are collectedusing standard methods (e.g., filtration, centrifugation) and thecollected cells and spores can be lyophilized, spray-dried, air-dried orfrozen. As described herein, the supernatant from the cell culture iscollected and used as an extracellular agent secreted by B. coagulans.

A typical yield from the above culture is in the range of about 10⁹ to10¹⁰ viable spores and more typically about 100 to 150 billioncells/spores per gram before drying. Spores maintain at least 90%viability after drying when stored at room temperature for up to tenyears, and thus the effective shelf life of a composition containing B.coagulans Hammer spores at room temperature is about 10 years.

Example 2: Preparation of Bacillus coagulans Spores

A culture of dried B. coagulans spores was prepared as follows. Tenmillion spores were inoculated into a one liter culture containing 24 gpotato dextrose broth, 10 g of enzymic-digest of poultry and fishtissue, 5 g of FOS and 10 g MnSO₄. The culture was maintained for 72hours under a high oxygen environment at 37° C. to produce culturehaving about 150 billion cells per gram of culture. Thereafter, theculture was filtered to remove culture medium liquid, and the bacterialpellet was resuspended in water and freeze-dried. The freeze-driedpowder is then ground to a fine powder using standard good manufacturingpractice (GMP).

Example 3. Baked Muffin with Micro-Encapsulated Bacillus coagulans

GBI-30, ATCC Designation Number PTA-6086, was microencapsulated (MaxxPerformance; Chester, N.Y.) and added in dry powder form to blueberrybran muffin batter. The final concentration of Bacillus coagulans (bothvegetative cells and spores) in the batter was about 20 billion (2×10¹⁰)CFU/5 lbs of batter (yield about 20 muffins). The final concentration ofBacillus coagulans (both vegetative cells and spores) in each muffin wasabout 1 billion (1×10⁶) CFU/muffin. The isolated Bacillus coagulanscomprised about 50 mg by weight per four ounce muffin. The muffins werecooked at 350° F. for 15 minutes. Subsequently, the muffins were frozenand stored at 0° F. for 14 days. The muffins were then thawed, crushed,and the number of viable bacteria was determined. Unexpectedly,approximately 41% of the bacteria in the muffin were viable after theabove-mentioned cooking and freezing cycle.

What is claimed is:
 1. A baked composition selected from the groupconsisting of a cake, a pie, a tart, a pastry, a candy bar, an energybar, a granola bar, a quiche, and a cookie comprising an edible starchand isolated Bacillus coagulans spores, and wherein said Bacilluscoagulans spores are applied prior to cooking the baked good and presentat a concentration of at least about 1×10⁷ to 1×10¹² CFU of spores/intof external surface of said baked composition.
 2. The baked compositionof claim 1, wherein said isolated Bacillus coagulans comprises between0.01% and 0.1% by weight of said baked composition.
 3. The bakedcomposition of claim 1, wherein said isolated Bacillus coagulans isBacillus coagulans Hammer strain Accession No. ATCC 31284, GBI-30strain, (ATCC Designation Number PTA-6086), GBI-20 strain (ATCCDesignation Number PTA-6085) or GBI-40 strain (ATCC Designation NumberPTA-6087).
 4. The baked composition of claim 1, further comprisingBacillus coagulans vegetative cells.
 5. The baked composition of claim1, further comprising a fat selected from the group consisting of oil,butter, shortening, artificial lipid, synthetic fat, and a fatsubstitute.
 6. The baked composition of claim 1, further comprising asugar, sugar substitute, or artificial sweetener.
 7. The bakedcomposition of claim 1, wherein said Bacillus coagulans spores have beenapplied as a powder.